ObsEva SA (OTCPK: OBSE.F)
Health Care · Biotechnology · CH
$0.00
+9900.00% today · 0.0% 1Y
ObsEva SA (OTCPK: OBSE.F) operates in the Biotechnology industry within the Health Care sector. The company is valued at $11.72K and employs 15 people.
Over the last twelve months the share price has gained 0.0%, trading between 0.00 and 0.05.
Tweenvest scores ObsEva SA across four factors: quality 27/100, value 55/100. Its strongest factor is value.
OBSE.F price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.72K
- Revenue (TTM)
- $19.64M
- P/E
- 0.00
- EPS
- 0.07
- Dividend yield
- —
- Beta (5Y)
- 20.16
- 52-week high
- $0.05
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 117.18M
- Employees
- 15
- Next earnings
- —
About ObsEva SA
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
- ISIN
- CH1260041939
- Founded
- 2012
- Listed since
- Jul 13, 2018
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.